Critical gases for critical issues: CO2 technologies for oral drug delivery

Author:

Danan Hana12,Esposito Pierandrea3

Affiliation:

1. SiTec PharmaBio, Baldiri Reixac 10, 08028 Barcelona, Spain

2. Sitec Consulting, BioIndustry Park, Via Ribes 5, 10010 Colleretto Giacosa (TO), Italy

3. SiTec PharmaBio, Baldiri Reixac 10, 08028 Barcelona, Spain. .

Abstract

In recent years, CO2-based technologies have gained considerable interest in the pharmaceutical industry for their potential applications in drug formulation and drug delivery. The exploitation of peculiar properties of gases under supercritical conditions has been studied in the last 20 years with mixed results. Promising drug-delivery technologies, based on supercritical CO2, have mostly failed when facing challenges of industrial scaleability and economical viability. Nevertheless, a ‘second generation‘ of processes, based on CO2 around and below critical point has been developed, possibly offering technology-based solutions to some of the current issues of pharmaceutical development. In this review, we highlight the most recent advancements in this field, with a particular focus on the potential of CO2-based technologies in addressing critical issues in oral delivery, and briefly discuss the future perspectives of dense CO2-assisted processes as enabling technologies in drug delivery.

Publisher

Future Science Ltd

Subject

Pharmaceutical Science

Reference140 articles.

1. European Environmental Agency.Pharmaceuticals in the environment. Results of an EEA workshop. Technical report No 1 /2010.European Environmental Agency. Copenhagen, Denmark,1725–2237 (2010).

2. European Medicines Agency.Road map to 2015. The European Medicines Agency‘s contribution to science, medicines and health. European Medicine Agency. Adopted by the Agency‘s Management Board on December 2010.European Medicines Agency. London, UK (2011).

3. Department of Health and Human Services, US Food and Drug Administration.Innovation, Stagnation, Challenge and Opportunity on the Critical Path to New Medical Products.Silver Spring, MD, USA (2004).

4. Department of Health and Human Services, US Food and Drug Administration.Pharmaceutical Development Q8 (R2). ICH Harmonized Tripartite Guidelines. Current Step 4 Version.ICH Expert Working Group. Geneva, Switzerland (2009).

5. Pharmaceutical Quality by Design: Product and Process Development, Understanding, and Control

Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3